Table 4.

Tumor Response Based on Modified Response Evaluation Criteria in Solid Tumors

Unmatched Group					Matched Group
	TACE-Lenvatinib (n = 39)	TACE (n = 148)	P value	OR (95% CI)	TACE-Lenvatinib (n = 34)	TACE (n = 68)	P value	OR (95% CI)
CR	3 (7.7%)	3 (2.0%)	0.202	4.03 (0.78–20.79)	3 (8.8%)	2 (2.9%)	0.330	3.19 (0.51–20.10)
PR	22 (56.4%)	51 (34.5%)	0.012	2.46 (1.20–5.05)	20 (58.8%)	25 (36.8%)	0.034	2.46 (1.06–5.71)
SD	6 (15.4%)	46 (31.1%)	0.052	0.40 (0.16–1.03)	4 (11.8%)	20 (29.4%)	0.048	0.32 (0.10–1.03)
PD	8 (20.5%)	48 (32.4%)	0.148	0.54 (0.23–1.26)	7 (20.6%)	21 (30.9%)	0.272	0.58 (0.22–1.54)
ORR	25 (64.1%)	54 (36.5%)	0.002	3.11 (1.49–6.48)	23 (67.6%)	27 (39.7%)	0.008	3.18 (1.33–7.56)
DCR	31 (79.5%)	100 (67.6%)	0.148	1.86 (0.80–4.35)	27 (79.4%)	47 (69.1%)	0.272	1.72 (0.65–4.58)

Abbreviations: TACE, transarterial chemoembolization; CR, complete response; PR, partial response; SD, stable response; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; OR, odds ratio; CI, confidence interval.